Feb 10, 2022 4:05 pm EST Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24 Read More
Jan 24, 2022 8:00 am EST Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria Read More
Jan 5, 2022 8:00 am EST Codexis to Participate in the H.C. Wainwright Virtual BioConnect Conference Read More
Dec 15, 2021 8:00 am EST Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing Read More
Nov 22, 2021 8:00 am EST Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021 Read More
Nov 15, 2021 8:00 am EST Codexis to Present Data Highlighting Two New Therapeutic Discovery Programs at the 14th International Congress of Inborn Errors of Metabolism 2021 Read More
Nov 15, 2021 8:00 am EST Codexis Appoints Two New Senior Leaders for Human Resources and Corporate Development Read More